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REVIEW CURRENTOPINION Abnormal red cell features associated with
hereditary neurodegenerative disorders: the
neuroacanthocytosis syndromesCopyright © Lippincott W
1065-6251  2014 Wolters Kluwera b cLucia De Franceschi , Giel J.C.G.M. Bosman , and Narla MohandasPurpose of review
This review discusses the mechanisms involved in the generation of thorny red blood cells (RBCs), known as
acanthocytes, in patients with neuroacanthocytosis, a heterogenous group of neurodegenerative hereditary
disorders that include chorea-acanthocytosis (ChAc) and McLeod syndrome (MLS).
Recent findings
Although molecular defects associated with neuroacanthocytosis have been identified recently, their
pathophysiology and the related RBC abnormalities are largely unknown. Studies in ChAc RBCs have
shown an altered association between the cytoskeleton and the integral membrane protein compartment in
the absence of major changes in RBC membrane composition. In ChAc RBCs, abnormal Lyn kinase
activation in a Syk-independent fashion has been reported recently, resulting in increased band 3 tyrosine
phosphorylation and perturbation of the stability of the multiprotein band 3-based complexes bridging the
membrane to the spectrin-based membrane skeleton. Similarly, in MLS, the absence of XK-protein, which is
associated with the spectrin–actin–4.1 junctional complex, is associated with an abnormal membrane
protein phosphorylation state, with destabilization of the membrane skeletal network resulting in generation
of acanthocytes.
Summary
A novel mechanism in generation of acanthocytes involving abnormal Lyn activation, identified in ChAc,
expands the acanthocytosis phenomenon toward protein–protein interactions, controlled by
phosphorylation-related abnormal signaling.
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In the 1960s Irving M. Levine and Critchley separ-
ately reported a newhereditary neurological disorder
characterized by hyporeflexia,mildmuscleweakness
and atrophy associated with thorny red cells, acan-
thocytes (Fig. 1) [1–4]. This disorder was described
as neuroacanthocytosis based upon the clinical
phenotype [3,4]. Today, neuroacanthocytosis syn-
dromes consist of chorea-acanthocytosis (ChAc),
McLeod syndrome (MLS), Hungtington’s disease
like-2 (HDL2) and pantothenate-kinase-associated
neurodegeneration (PKAN) [5]. Acanthocytes are
one of the biological hallmarks of neuroacanthocy-
tosis. The analysis of the abnormal red blood cells
(RBCs) from neuroacanthocytosis patients, to define
themechanistic basis for the red cell phenotype, will
further help our understanding of the pathogenesis
of neuroacanthocytosis.illiams & Wilkins. Unau
Health | Lippincott Williams & WilkNORMAL RED CELL MEMBRANE
ORGANIZATION AND RED CELL SHAPE
The study of human RBCs has led to the develop-
ment of a general model of RBC membrane organ-
ization based on the functional cross-talk between
the membrane lipid bilayer, the integral membranethorized reproduction of this article is prohibited.
ins www.co-hematology.com
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KEY POINTS
 Acanthocytes are a marker of neuroacanthocytosis, a
set of hereditary neurodegenerative diseases affecting
the basal ganglia.
 In ChAc, acanthocytosis has been related to increased
Lyn activation and alteration of band 3-based protein–
protein interactions involved in stability of the RBC
membrane skeletal network.
 In MLS, the absence or reduction of XK protein, part of
the 4.1 multiprotein complex anchoring the membrane
to the cytoskeleton, is associated with a perturbation of
the membrane protein phosphorylation state.
 In other neuroacanthocytosis diseases, breakdown
products of band 3 and alterations in the interaction of
band 3 with neighboring partner proteins have
been observed.
Erythroid system and its diseasesproteins such as band 3 and the peripheral pro-
teins such as spectrins and actin (Fig. 2). The
RBC membrane is anchored to the membrane
skeleton network through the band 3-based bridges
formed bymultiprotein complexes involving ankrin
and protein 4.1 (or junctional complex) (Fig. 2)
[6–14]. The study of hereditary RBC disorders has
provided insight into the RBC membrane organiz-
ation and function. Mutations in proteins involved
in the vertical interactions such as band 3 or ankyrin
with membrane skeleton result in loss of membraneopyright © Lippincott Williams & Wilkins. Unautho
Normal RBCs Ch
FIGURE 1. Upper panel. The brightfield images of fixed and per
from a patient with chorea-acanthocytosis (ChAc). Lower panel. T
with the anti-band 3 antibody of fixed and permeabilized red cel
images were captured by a confocal laser-scanning microscope (
aperture water immersion lens equipped with LAS AF software. Th
(http://rsb.info.nih.gov/ij/).
2 www.co-hematology.comsurface area and generation of spherocytes as in
patients with hereditary spherocytoses. However,
mutations in proteins affecting lateral interactions
such as spectrin dimer–dimer or spectrin–actin–
protein 4.1 interactions result in loss of RBC
membrane mechanical stability and generation of
elliptocytes, as in patients with hereditary ellipto-
cytosis (Fig. 2) [8].
Although these RBC shape abnormalities have
been related to genes encoding for membrane
and skeletal proteins, abnormal RBC morphology
has been also described in diseases primarily
affecting the lipid bilayer such as abetalipoprotei-
nemia and spur cell anemia. Hypercholesterolemic
mice generated by inactivation of SR-BI (SR-BI/),
a gene encoding the high-density lipoprotein
receptor, have macrocytic anemia with abnormal
circulating RBCs and large membrane-enclosed
intracellular inclusions [15]. The severity of the
SR-BI/ hematological phenotype was related to
the cellular cholesterol content, suggesting that
cholesterol is important in erythroid maturation
and in generation of normal RBCs [15]. In patients
with abetalipoproteinemia or hypobetalipopro-
teinemia, the deficiency of apolipoprotein B is
associated with acanthocytosis and neurological
manifestation but without movement disorders
such as those seen in the neuroacanthocytosis
syndromes [5]. Changes in the composition of
RBC membrane lipids have been also associated
with the generation of acanthocytes in spur cell
anemia, which occurs in patients with advancedrized reproduction of this article is prohibited.
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FIGURE 2. Schematic diagram of membrane organization in normal red blood cells (RBCs) and acanthocytes from patients
with chorea-acanthocytosis (ChAc, changes are indicated in blue) and McLeod Syndrome (MLS, changes are indicated in
light brown). B3, band 3; 4.2, protein 4.2; 4.1, protein 4.1; Kell, Kell glycoprotein; XK, XK protein; GPA, glycophorin A;
GPC, glycophorin C; LW: Landsteiner-Weiner blood group glycoprotein; RhAG: Rh-associated glycoprotein; p55: protein 55;
Glut1: glucose transporter-1; P-ST, phospho-serine-threonine; P-Y, phospho-tyrosine membrane associated proteins; ge, Ne
(g-glutamyl) lysine isopeptide; CK, casein kinase. The absence of XK protein and the reduction in Kell protein as observed in
MLS red cells is represented by the dashed lines of lighter forms.
The neuroacanthocytosis syndromes De Franceschi et al.liver failure and resolves after liver transplantation
[16].
In the present review, we focus on acanthocy-
tosis in neuroacanthocytosis, summarizing the
recent advances in our knowledge on the mechan-
isms underlying the generation of acanthocytes in
neuroacanthocytosis syndromes.CHOREA-ACANTHOCYTOSIS
Chorein is the 360-kDa protein product of the
VPS13A gene (chromosome 9), mutations of which
are associated with the autosomal recessive disorder
of ChAc [5,17,18]. Chorein is present in mature
RBCs and is partially or completely absent in ChAcCopyright © Lippincott Williams & Wilkins. Unau
1065-6251  2014 Wolters Kluwer Health | Lippincott Williams & WilkRBCs [19]. At the present, the lack of information
regarding the biochemical structure and inter-
actions of chorein with other proteins makes it
difficult to formulate a hypothesis on its role in
RBC homeostasis (Table 1) [20–24,25
&&
,26–31,32
&
,
33–39].
In ChAc RBCs, electron microscopic studies
have revealed a heterogeneous distribution of the
membrane skeleton characterized by condensated
cytoskeletal structures around protrusions and less
filamentous structure in some large patches of
the membrane (Table 1) [21]. Although no major
abnormalities in RBC membrane protein compo-
sition and abundance have been observed in ChAc
RBCs, an increased amount of Ne (g-glutamyl) lysinethorized reproduction of this article is prohibited.
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Table 1. Summary of the genetic and hematological features of neuroacanthocytosis syndromes
Disease
Mode of
inheritance
Gene
(location)
Protein
product Acanthocytes/anemia Red cell alterations Refs.
ChAc AR VPS13A (9q21) Chorein þþþ/No anemia Low RBC Kþ content and
subpopulation of dense RBCs
[20]
Heterogenous distribution of RBC
membrane skeleton
[21]
Increased band 3 Ser-Threo-
phosphorylation
[22]
Increased casein kinase (CK)
membrane activity
[22]
Increased band 3, p55, protein
4.1, actin Tyr-phosphorylation
[22,23]
Increased Lyn activity [23]
Increased Ne(g-glutamyl)lysine
isopeptide RBC membrane
association
[24]
Reduced response to drug induced
endovesicle formation
[25&&]
MLS X-linked XK (Xp21) XK protein þþþ/Mild compensated
hemolytic anemia
Absent or truncated XK protein [26]
Reduced Kell glycoprotein [27–29&]
Low RBC Kþ content and
subpopulation of dense RBCs
[30]
Decreased deformability of MLS
RBCs by ektacytometry
[31]
Heterogenous distribution of RBC
membrane skeleton
[21]
Increased Tyr-phosphorylation
pattern of RBC membrane
proteins
[32&]
HDL2 AD JPH3 (16q24.3) Junctophilin-3 þþ/No anemia Proteolytic band 3 products [33]
Increased small G proteins RBC
membrane associated
[34]
PKAN AR PANK2 (20p.13) Pantothenate
kinase 2
/No anemia Reduced response to drug induced
endovesicle formation in
acanthocytic but not in normally
shaped RBCs
[25&&,35–39]
þþ, acanthocytes present between 30 and 35%; þþþ, acanthocytes present between 25 and 60% of the whole red cell population; , acanthocytes 3%; AD,
autosomal dominant; AR, autosomal recessive; ChAc, chorea-acanthocytosis; HDL2, Huntington’s disease-like 2; JPH3, junctophiln-3; MLS, McLeod syndrome;
PKAN, pantothenate kinase-associated neurodegeration; PS, phosphatidylserine; RBC, red blood cell; Ser-Threo, serine–threonine; Tyr, tyrosine.
Erythroid system and its diseasesisopeptide associated with RBC membrane was
reported in a small number of ChAc patients
(Table 1) [24,40]. Transglutaminase 2 catalyzes
the organization of multicomplex protein cross-
linked by the Ne (g-glutamyl) lysine isopeptide.
The main protein involved is band 3 through its
Gln-30 residues, together with bridging proteins
such as ankyrin or protein 4.1 and skeletal proteins
such as spectrins [40–42]. A recently described
enrichment of actin in the Triton-soluble fraction
of ChAc RBCs supports earlier data showing a
perturbation of the skeletal network and possible
instability in bridging band 3-based multiprotein
complexes in the absence of chorein [43]. This find-
ing is also supported by the observation of a reduced
response of ChAc red cells to drugs inducing endo-
vesicles [25
&&
] In addition, a reduced RBCKþ content
has been described in ChAc patients [20]. These data
suggest amore complex scenario inChAc thatmightopyright © Lippincott Williams & Wilkins. Unautho
4 www.co-hematology.cominvolve posttranslational modifications such as
phosphorylation affecting protein–protein inter-
actions between membrane proteins and skeletal
network. Indeed, recent in-vitro studies have shown
that an imbalance between phosphatase-kinase
activities might result in an altered band 3 phos-
phorylation state [11,12,44]. This might affect the
stability of the complexes involving band 3, bridg-
ing themembrane to the skeletal network [22,23,45]
(Fig. 2). In RBCs, Syk, a Src-related kinase, and Lyn, a
Src kinase, are part of the signaling pathway target-
ing band 3 and affecting its protein interactions [46].
In ChAc RBCs, we recently studied the tyrosine
(Tyr)-phosphoproteome and found an increased
Tyr-phosphorylation state of several membrane
proteins, including band 3, compared with controls
[23]. We observed an increased phosphorylation of
the Tyr-904 residue on band 3, which is a functional
target of Lyn, but not of the Tyr-8 residue that is arized reproduction of this article is prohibited.
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The neuroacanthocytosis syndromes De Franceschi et al.target of Syk (Fig. 2). We demonstrated an abnormal
Lyn activation independent from its canonical path-
way through the primary Syk activation. We then
postulated that the ChAc-associated alterations in
RBC membrane protein organization are the result
of increased Tyr-phosphorylation state leading to an
altered linkage of band 3 to the junctional com-
plexes, and generation of acanthocytes (Fig. 2). This
conclusion is also supported by the recent obser-
vations that the blood of mice with constitutively
active Lyn contains acanthocytes [47
&&
]. To date,
there are not consistent data implicating an altered
membrane lipid composition in acanthocytosis in
ChAc [20].
ChAc presents clinically in young adulthood
[5,48]. An increased serum creatine kinase may
precede the neurological symptoms, and sometimes
is associated with hepatosplenomegaly [5,48]. At the
present, 120 mutations in the VPS13A gene of var-
ious types have been described, resulting in low or
absent synthesis of chorein or normal expression of
a functionally defective protein [17,49].
VSP13A is a member of the VPS13 family
(VPS13A–D) [50,51]. A comparison of the human
gene sequence with those of other organisms has
shown large similarities of the human protein
VPS13A with the yeast Vps13p protein and the
Dictyostelium discoideum TipC proteins, whereas
the other VSP13 genes seem to result from more
recent evolutionary events [52,53]. Vps13p protein
is involved in trafficking of various transmembrane
proteins, in particular in the recruitment of three
membrane proteins to the trans-Golgi network:
Kex2p, a Golgi-endoprotease; Ste13p, a dipeptidyl
aminopeptidase; and Vps10p, a cargo-sorting
receptor, which delivers the cargo enzymes to the
prevacuolar compartment similar to human late
endosome [54–56].
Human chorein has been recently cloned and
expressed in various cell lines [50]. Confocal micro-
scopy showed a cytoplasmic localization of chorein
in a vesicular-like pattern [50].
A mouse model with a VPS13A deletion showed
reduced expression of chorein and production
of truncated protein (Table 2 [57–61,62
&
,63–66]).
These ChAc mice developed a mild, late-onset
motor disturbance with late adult onset and acan-
thocytes with increased osmotic fragility; however,
no functional studies have been reported [57,58].McLEOD SYNDROME
The XK protein (444 amino acid residues, contain-
ing the Kx antigen) is the membrane protein associ-
ated with MLS, which is an X-linked form of
neuroacanthocytosis [26–28,67]. The XK proteinCopyright © Lippincott Williams & Wilkins. Unau
1065-6251  2014 Wolters Kluwer Health | Lippincott Williams & Wilkis predicted to have 10 transmembrane domains
with structural characteristics of a membrane trans-
porter protein, but its function is yet to be defined.
In the RBC membrane, the XK protein (50kDa) is
covalently linked to the Kell glycoprotein (93kDa)
by a single disulfide bond (XK Cys347–Kell Cys72)
and is part of the multiprotein 4.1 junctional com-
plex (Fig. 2) [29,68,69]. In MLS RBCs, truncation of
the XK protein is associatedwith reduced expression
of the Kell blood group antigen and a compensated
hemolytic anemia [70–73].
Functional studies of MLS RBCs have shown
a reduced resistance to mechanical stress and
increased RBC density associated with reduced
RBCKþ content (Table 1) [21,30,31,74–76]. Electron
microscopic studies demonstrate a heterogeneous
distribution of the RBC membrane skeleton, mainly
present in the denser RBC fraction containing acan-
thocytes [20,21,26].
The abnormal Tyr-phosphorylation state of
some membrane proteins in MLS RBCs indicates
once more an involvement of posttranslational
modifications and/or disturbed intracellular signal-
ling in acanthocyte formation (Table 1) [34,76].
Preliminary investigations of the RBC membrane
phosphoproteome showed that the RBC membrane
Tyr-phosphorylation pattern was significantly
different in MLS RBCs compared with controls.
More specifically, an increased Tyr-phosphorylation
state of ankyrin and protein 4.1 was found in MLS
RBCs [32
&
]. In this regard, it may be relevant that
changes in protein 4.1 phosphorylation state affect
RBC membrane mechanical stability [77]. Further-
more, RBCs of protein 4.1 knockout mice (4.1/)
show a perturbation of the RBC membrane multi-
protein complexes involving glycophorin C, XK,
Duffy and Rh proteins [78]. In MLS, it is likely that
besides a reduction of XK–Kell complex, multiple
factors contribute to an alteration of RBCmembrane
stability, such as changes in protein phosphoryl-
ation state, resulting in a destabilization of the
skeletal network with generation of acanthocytes
(Fig. 2).
MLS is found worldwide, and has a variable
clinical presentation, with a mean age of onset
between 30 and 40 years. It is mainly characterized
by chorea, generalized seizures, neuropsychiatric
abnormalities, cardiac myopathy, mild hemolytic
anemia with acanthocytosis and hepatospleno-
megaly [5,71]. The majority of the 28 identified
XK mutations comprise small and large (5Mb)
deletions, frameshift and nonsense mutations,
resulting in an absent or truncated XK protein
[5,71]. Two missense mutations in the XK gene
and one single nucleotide mutation in an intron
near the splice junction have been reported asthorized reproduction of this article is prohibited.
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Table 2. Animal models developed to study neuroacanthocytosis syndromes
Disease Animal models Phenotype Refs.
ChAc Engineered mouse strain carrying with
deletion of VPS13A gene
Reduced chorein protein expression in whole brain homogenate [57,58]
Male infertility
Abnormal RBC morphology and increased osmotic fragility in
aged mice (>70 weeks of age)
Behavioral abnormalities in aged mice (>70 weeks of age)
Reduced striatum/whole brain ratio
HDL2 Mice JPH3/ No or mild neurological phenotype [59]
Mice JPH3/ JPH4/ Cognitive and motor deficiencies [60]
No data on RBC features
MIce BAC-HDL2 Age dependent motor deficiency
Neuronal phenotype of HDL2
No data on RBC features
PKAN Mice PANK2/ Retinal degeneration, male inferility, no dystonia and little
alteration in basal ganglia, no brain iron accumulation
[61,62&]
No data on RBC features
Normal mice treated with pantothenate
kinase inhibitor or with diet absent in
pantothenic acid
Movement disorders and azoospermia, no brain iron
accumulation in basal ganglia
No data on RBC features
[63,64]
Drosophila melanogaster with insertion of
human PANK2 mutation on flb gene
Shortened lifespan [65,66]
Male infertility
Progressive locomotion defect
Degeneration in central nervous system and retina, but without
neuronal iron accumulation
ChAc, chorea-acanthocytosis; HDL2, Hungtinon’s disease like-2; mice BAC-HDL2, bacterial artificial chromosome transgenic mice; mice JPH3/ JPH4/, mice
genetically lacking junctophilin-3 and 4; mice JPH3/, mice genetically lacking junctophilin-3; mice PANK2/, mice genetically lacking pantothenate kinase 2;
NA, neuroacanthocytosi; PKAN, pantothenate kinase 2 associated neurodegeneration; RBC, red blood cell.
Erythroid system and its diseasescausing MLS with a milder clinical phenotype
[5,26]. The XK protein is ubiquitously expressed
[5]. Phylogenetic analysis showed that XK protein
is amember of the XK family of proteins, containing
XPLAC and XTEST proteins that share 37% and 31%
homology, respectively, with XK. These proteins
have a common domain with a consensus sequence
that shares homologies with the ced-8 protein from
the nematode Caernorhabditis elegans [29,79]. Ced-8
is involved in regulation of apoptosis in C. elegans,
but it is not known whether XK plays a similar role
in RBCs, erythoid precursors or in neuronal cells.HUNTINGTON DISEASE-LIKE 2
Acanthocytes have been observed in patients with
Huntington’s disease-like 2 (HDL2), an autosomal
dominant neurodegenerative disorder resembling
Huntington’s disease. In HDL2, acanthocytosis-
specific changes in membrane organization are
suggested by the presence of band 3 breakdown
products [80] and by the in-vitro production of
vesicles that are different from the vesicles of control
RBCs [34]. Preliminary RBC membrane proteomic
analysis suggested that proteasome components
and small G proteins were increased in HDL2
patients compared with controls [34]. Recently, it
has been reported that RBCs from mice geneticallyopyright © Lippincott Williams & Wilkins. Unautho
6 www.co-hematology.comlacking the small G protein Rac GTPase have
a perturbation of dynamic regulation of the RBC
membrane skeletal network [81]. This suggests a
possible involvement of small G proteins in mem-
brane skeletal rearrangement in acanthocytosis in
HDL2 (Table 2).
HDL2 is caused by a CAG/CTG expansion
mutation in exon 2A of the junctophilin-3 gene
(JPH3) on chromosome 16q24.3 [82]. HDL2 has only
been identified in individuals of African descent,
in mid-life, with involuntary movements, neuro-
psychiatric symptoms and dementia [82,83]. Post-
mortem studies of HDL2 patients have shown
intranuclear aggregates that were labeled with anti-
ubiquitin antibodies and with anti1C2 antibody
against long polyglutamine tracts in striatum and
cortex, similar to those observed in Huntington’s
disease [80,84]. To date, it is not known how these
aggregates might contribute to the neurological
damage of HDL2. Mice genetically lacking the
JPH3 protein present a verymild phenotype,whereas
cognitive and motor deficiencies were only present
when both JPH3 and JPH4 genes were knocked out
simultaneously, suggesting a more complex patho-
genesis of HDL2 disease than the loss of JPH3 func-
tion (Table 2) [59]. A recently developed bacterial
artificial chromosome-transgenic mouse model for
HDL2 [60] shows age-dependent motor deficiencyrized reproduction of this article is prohibited.
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The neuroacanthocytosis syndromes De Franceschi et al.and a pathological HDL2 neuronal phenotype, but
no data are reported on RBC features (Table 2).PANTOTHENATE KINASE-ASSOCIATED
NEURODEGENERATION
Acanthocytes are also found in approximately 10%
of the pantothenate kinase-associated neurodegen-
eration (PKAN) patients [35]. Data from preliminary
proteomic experiments indicate a PKAN RBC mem-
brane protein composition different from both con-
trol and other neuroacanthocytosis RBCs (Bosman
et al., unpublished data). A recent study has shown
reduced response of acanthocytic PKAN RBCs but
not of normal shaped PKAN RBCs to drug-induced
endovesicle formation [25
&&
]. We know of no
other detailed studies on RBCs from PKAN patients.
PKAN is an autosomal recessive disease caused by
mutations in the human PANK2 gene on chromo-
some 20p13 encoding for the pantothenate kinase
2 protein isoforms, which are localized inmitochon-
dria [36–38,85]. PANK2 is a key enzyme in the
biosynthesis of coenzyme A (CoA), which is import-
ant for energymetabolism, and fatty acid and neuro-
transmitter metabolism. A founder mutation effect
has been described in the Netherlands [39]. The
typical onset of PKAN is in childhood. A specific
pattern of brain iron accumulation in the globus
pallidus results in the eye-of-the-tiger pattern on
magnetic resonance imaging [35,36].
Down-regulation of PANK2 expression in vitro in
different cell lines resulted in reduced cell growth
related to irondeficiencywithoutmitochondrial iron
deposition, associated with a significant increase in
ferroportin [86]. As ferroportin is involved in iron
homeostasis through thehepcidin–ferroportin path-
way and might be also important in regulation of
brain iron levels, ferroportin has been suggested to
play a role in the altered iron transport to brain
observed in PKAN patients [86]. Mice genetically
lacking PANK2 ( pank2-/-) show retinal degeneration,
mitochondrial neuronal dysfunction andmale infer-
tility, but no dystonia and only minor alterations in
the basal ganglia (Table 2) [61,62
&
]. Normal mice
treated with either pantothenate kinase inhibitor
or on a diet without pantothenic acid developmove-
ment disorders andmale infertility but show no iron
accumulation in the basal ganglia (Table 2) [63,64].
Thus, to date, mouse models seem to be of limited
used in the study of PANK. However, three human
mutations of PANK2 have been expressed in the fbl
gene inDrosophilamelanogaster, corresponding to the
human PANK2 gene. In these flies, the decrease in
pantothenate kinase activity correlated with the
severity of the phenotype (Table 2). This represents
an interesting model to study PKAN, even if theCopyright © Lippincott Williams & Wilkins. Unau
1065-6251  2014 Wolters Kluwer Health | Lippincott Williams & Wilkobserved neurodegenerationwas not associated with
neuronal iron accumulation [65,66].CONCLUSION
The significance of the combination of neuronal
degeneration in the basal ganglia with the for-
mation of acanthocytes in patients with various
neuroacanthocytosis syndromes is still far from
being understood. Recent proteomic and functional
data on RBC from ChAc and MLS patients confirm
previous evidence on the central role of band 3 in
acanthocyte formation, and expand the acanthocy-
tosis phenomenon toward protein–protein inter-
actions, controlled by phosphorylation-related
signaling [34]. This opens new diagnostic possibil-
ities, and suggests that, in principle, signaling-based
intervention is possible. At present, the clinical
approach to the neuroacanthocytosis syndromes
is essentially symptomatic with a combination of
medical therapy to reduce involuntary movements
and/or neurosurgery with deep brain stimulation or
ablative procedures, although the latter remains to
be validated in a large cohort of patients [87]. In
view of the specific and characteristic association of
acanthocytosis with neurodegeneration, RBCs con-
stitute a promising target for futuremechanistic and
functional studies.
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